Skip to main content
ENSG logo

ENSG · Ensign Group, Inc

Track ENSG — free
$186.02 -2.21 (-1.17%) At close · Nov 17
Market Cap
$10.85B
Shares
58.34M
Volume · Nov 17 244.85K Avg daily vol (3M) 353.89K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$186.02 Open$185.92 Day$185.30–187.98 52W close$147.13–215.83 Avg vol 30d367K Short int1.5M · 2.5% of shares · 3.5d Short vol38% Last earningsOct 28, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 27

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Oct 27
Current report 8-K
Financial results

The Ensign Group, Inc. reported third-quarter diluted EPS of $1.76, adjusted EPS of $2.03 and revenue of $1.48 billion. It raised 2026 earnings guidance to $7.94 to $8.02 per diluted share from $7.75 to $7.85.

Read from the first part of this long document
Oct 27
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

Ensign Group expanded during the nine months ended September 30, 2026 by adding 23 stand-alone and two campus operations, 2,974 beds and 135 senior living units, then entered Florida after adding 18 stand-alone and two campus operations.

Revenue $1.48B ▲ 14.5% Net income $104.26M ▲ 24.4% Diluted EPS $1.76 ▲ 23.9%
Read from the MD&A section
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.67B
Trailing 12 months
Net income (TTM)
$399.12M
Trailing 12 months
Revenue growth YoY
+14.5%
Year over year
Operating margin
9.0%
Trailing 12 months
P / E (TTM)
27.7
Trailing earnings · reciprocal yield 3.6%
FCF yield
—
TTM · current market cap
Return on invested capital
16.1%
Trailing 12 months
Net cash
$192.97M
Latest balance sheet
Dividend yield
0.1%
Trailing 12 months
Shares change YoY
+0.6%
Year over year · more shares
Price change (1Y)
+4.8%
Trailing year
Short interest
2.5%
Latest settlement · 3.5 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 29, 2026
Q2 FY26

TL;DR. Ensign reported record Q2 2026 results with adjusted EPS of $1.92 (+20.8% YoY) and raised its full-year 2026 earnings guidance to $7.75–$7.85 per diluted share and revenue guidance to $5.87–$5.92 billion, driven by occupancy gains, skilled mix expansion, and continued acquisitions.

Bullish
  • + Raised full-year 2026 EPS guidance to $7.75–$7.85 from $7.48–$7.62 and revenue guidance to $5.87–$5.92 billion from $5.81–$5.86 billion.
Bearish
  • − Recently acquired Texas facilities carry higher purchase prices, lower-than-average occupancies, and 'significant clinical and operational hurdles' that will take time to deliver expected returns.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg +5%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 57%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +6%
trailing
6-month return +9%
trailing
YTD return +7%
this year
Relative strength +12%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $177 › 200d $182 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +74 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.52% of shares out · ▲ +5.5% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
569 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Excellent
Revenue growth +19%
Y/Y
EPS growth +14%
Y/Y
Free cash flow $492.7M
Valuation P/E 27.7
in line
Buyback $52.6M
remaining
Balance sheet $362.1M
net cash
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −32%
past year
ATR 2.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 8
Latest guidance · from the Earnings Call filed Jul 29, 2026
Annual earnings guidance · annual 2026 Maintained $7.75 – $7.85
Jul 27, 2026 $7.75 – $7.85 changed to Jul 29, 2026 $7.75 – $7.85
prior FY $5.84 midpoint +33.6% Y/Y
Annual revenue guidance · annual 2026 Maintained $5.87B – $5.92B
Jul 27, 2026 $5.87B – $5.92B changed to Jul 29, 2026 $5.87B – $5.92B
prior FY $5.06B midpoint +16.6% Y/Y
Guided vs delivered · last 8 settled
Annual revenue guidance annual 2025
guided $5.05B – $5.07B
$5.06B In line
Annual revenue guidance annual 2024
guided $4.2B – $4.22B
$4.26B Beat +1.2%
Diluted earnings per share annual 2023
guided $4.73 – $4.79
$3.65 Miss −23.3%
Annual revenue annual 2023
guided $3.72B – $3.73B
$3.73B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
57% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $177 › 200d $182 — 200d above 50d
Institutional flow Accumulating
+1% holders QoQ · +74 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.52% of shares out · ▲ +5.5% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
569 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $147 Now $186 · 57% Range high $216
vs 200-day avg +2% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Actual patient days 3,017,641 three months ended June 30, 2026 filing —
Actual patient days - Recently Acquired Facility 447,826 three months ended June 30, 2026 filing —
Actual patient days - Same Facility 2,164,347 three months ended June 30, 2026 filing —
Actual patient days - Transitioning Facility 405,468 three months ended June 30, 2026 filing —
Adjusted Earnings Per Share non-GAAP $1.92 Three Months Ended June 30, 2026 filing —
Adjusted EBITDA non-GAAP $181.15M Three Months Ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
EBITDA $162.28M (the result of another reconciliation in this filing)
+$16.17M Stock-based compensation expense
+$2.18M Costs incurred related to system implementations
+$0K Loss (gain) on long-lived assets and business interruption recoveries
+$519K Acquisition related costs
= Adjusted EBITDA $181.15M
Adjusted EBITDAR non-GAAP $247.56M Three Months Ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
Adjusted EBITDA $181.15M (non-GAAP)
+$66.41M Rent—cost of services
= Adjusted EBITDAR $247.56M
Adjusted EBT non-GAAP $152.54M Three Months Ended June 30, 2026 filing —
Adjusted Net Income non-GAAP $114.31M Three Months Ended June 30, 2026 filing —
Dollar value of common stock repurchased $40M three months ended June 30, 2026 filing —
EBITDA non-GAAP $162.28M Three Months Ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP Net income $99.83M
-$96K Less: Net income attributable to noncontrolling interests
-$4.63M Less: Interest income
+$33.84M Add: Provision for income taxes
+$31.41M Add: Depreciation and amortization
+$1.93M Add: Interest expense
= EBITDA $162.28M
FFO non-GAAP $24.75M three months ended June 30, 2026 filing —
FFO for Standard Bearer non-GAAP $24.75M Three Months Ended June 30, 2026 filing —
Number of campuses at period end 32 Three Months Ended June 30, 2026 filing —
Number of facilities at period end 348 Three Months Ended June 30, 2026 filing —
Number of facilities at period end - Recently Acquired Facility 64 three months ended June 30, 2026 filing —
Number of facilities at period end - Same Facility 234 three months ended June 30, 2026 filing —
Number of facilities at period end - Transitioning Facility 50 three months ended June 30, 2026 filing —
Occupancy percentage — Operational beds 82.9% three months ended June 30, 2026 filing —
Occupancy percentage — Operational beds - Recently Acquired Facility 76.6% three months ended June 30, 2026 filing —
Occupancy percentage — Operational beds - Same Facility 84.1% three months ended June 30, 2026 filing —
Occupancy percentage — Operational beds - Transitioning Facility 84.7% three months ended June 30, 2026 filing —
Same Facilities occupancy 84.1% the three months ended June 30, 2026 filing —
Shares of common stock repurchased 257K three months ended June 30, 2026 filing —
Skilled Mix (Days) 31% Three Months Ended June 30, 2026 filing —
Skilled Mix (Revenue) 50% Three Months Ended June 30, 2026 filing —
Skilled mix by nursing days - Recently Acquired Facility 26.9% three months ended June 30, 2026 filing —
Skilled mix by nursing days - Same Facility 32.2% three months ended June 30, 2026 filing —
Skilled mix by nursing days - Transitioning Facility 29.7% three months ended June 30, 2026 filing —
Skilled mix by nursing revenue - Recently Acquired Facility 45.1% three months ended June 30, 2026 filing —
Skilled mix by nursing revenue - Same Facility 51% three months ended June 30, 2026 filing —
Total skilled nursing revenue - Average daily revenue rate $435.1 three months ended June 30, 2026 filing —
Transitioning Facilities occupancy 84.7% the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ENSG
Ensign Group, Inc
this stock
$10.85B +6.8% +18.7% 27.7 2.5%
HCA
HCA Healthcare, Inc.
$104.69B +7.4% +7.1% 16.6 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.30B +3.1% — — 0.0%
THC
Tenet Healthcare Corp
$22.45B +41.9% +0.9% 8.2 2.2%
EHC
Encompass Health Corp
$13.53B +29.9% +10.5% 21.5 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
569
% held
90.0%
Net QoQ
-233.7K sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
502
View
Short & Settlement
Short Interest Rising
Shares short
1.5M
Days to cover
3.5d
Change
+76.2K sh
View
Short Volume
Short vol %
38%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$280.8K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
39.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$5.1B
Net income (FY)
$344.0M
EPS diluted
$5.84
View
Buybacks
Authorized
$100.0M
Remaining
$52.6M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 27, 2026
This year
16

The Ensign Group, Inc. reported third-quarter diluted EPS of $1.76, adjusted EPS of $2.03 and revenue of $1.48 billion. It raised 2026 earnings guidance to $7.94 to $8.02 per diluted share from $7.75 to $7.85.

View
Proposed Sales
Value
$18.0K
Shares
100
Filed
Oct 16, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 18, 2026
Last webcast
Oct 28, 2026
View
Investor Relations
Latest news
The Ensign Group to Present at th…
Published
Nov 12, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ENSG +0.5% +5.7% +8.8% +2.5% +6.8%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +2.8% +10.5% +11.8% +5.6% -0.6%

Capital returns

Latest dividend
$0.065 / share · ex Sep 30, 2026
Raised 3.2%
Paid (TTM)
$0.26 / share · 4 payouts
Dividend yield (TTM, derived)
0.14%
Full dividend history
Buyback program · as of Sep 30, 2026
Authorized
$100.00M
Spent (derived)
$47.43M
Remaining
$52.57M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1125376 CUSIP 29358P101 13F (30d) 568 filings 523 filers Visit website Investor relations